Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
DYDyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc. (DYN)

NASDAQ Global Select · Currency in USD
$15.62 ▼ -0.15 (-0.95%)
At close: Oct 23, 4:00 PM ET. Market closed.
$15.62 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$15.77
Open
$15.89
Day's Range
$15.32 – $15.89
52 Week Range
$14.00 – $27.31
Volume
2,134,278
Avg. Volume
2,810,867
Market Cap
$2.92B
Beta (5Y Monthly)
1.12
PE Ratio (TTM)
--
EPS (TTM)
-$3.14
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$35.20

Profile: Dyne Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
289
CEO
John G. Cox

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.91
DateEst.Actual
Jul 30, 2026-$0.75-$1.08Miss
May 11, 2026-$0.77-$0.73Beat
Mar 2, 2026-$0.74-$0.76Miss
Nov 5, 2025-$0.81-$0.76Beat
Jul 28, 2025-$0.99-$0.97Beat
May 8, 2025-$0.88-$1.05Miss

Analyst view

Consensus price target
$35.20 ▲ +125.4%
Range $24.00 – $50.00
Rating: Buy
Buy 86% · Hold 7% · Sell 7%

Get free alerts on DYN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.